Andros Pharmaceuticals Co.,Ltd
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment… Read more
Andros Pharmaceuticals Co.,Ltd (6917) - Net Assets
Latest net assets as of June 2025: NT$357.37 Million TWD
Based on the latest financial reports, Andros Pharmaceuticals Co.,Ltd (6917) has net assets worth NT$357.37 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$395.95 Million) and total liabilities (NT$38.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$357.37 Million |
| % of Total Assets | 90.26% |
| Annual Growth Rate | 25.43% |
| 5-Year Change | 336.23% |
| 10-Year Change | N/A |
| Growth Volatility | 127.95 |
Andros Pharmaceuticals Co.,Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Andros Pharmaceuticals Co.,Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Andros Pharmaceuticals Co.,Ltd (2019–2024)
The table below shows the annual net assets of Andros Pharmaceuticals Co.,Ltd from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$394.17 Million | -16.33% |
| 2023-12-31 | NT$471.11 Million | +68.56% |
| 2022-12-31 | NT$279.48 Million | +307.04% |
| 2021-12-31 | NT$68.66 Million | -24.01% |
| 2020-12-31 | NT$90.36 Million | -28.79% |
| 2019-12-31 | NT$126.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Andros Pharmaceuticals Co.,Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26063400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$447.72 Million | 113.58% |
| Other Components | NT$394.39 Million | 100.06% |
| Total Equity | NT$394.17 Million | 100.00% |
Andros Pharmaceuticals Co.,Ltd Competitors by Market Cap
The table below lists competitors of Andros Pharmaceuticals Co.,Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ELQ SA
WAR:ELQ
|
$6.73K |
|
GAMMA CIVIC LTD
SEM:GCL
|
$6.73K |
|
Commercial Bank of Ceylon PLC
CM:COMBN0000
|
$6.74K |
|
IRB InvIT Fund
NSE:IRBINVIT
|
$6.74K |
|
Foreveren
WAR:FOR
|
$6.72K |
|
CPC
VN:CPC
|
$6.71K |
|
Cleantech Biofuels Inc
PINK:CLTH
|
$6.71K |
|
Fideicomiso Irrevocable F/2061 FHipo
MX:FHIPO14
|
$6.70K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Andros Pharmaceuticals Co.,Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 471,107,000 to 394,173,000, a change of -76,934,000 (-16.3%).
- Net loss of 78,279,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-78.28 Million | -19.86% |
| Other Changes | NT$1.34 Million | +0.34% |
| Total Change | NT$- | -16.33% |
Book Value vs Market Value Analysis
This analysis compares Andros Pharmaceuticals Co.,Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.84x to 2.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$3.35 | NT$22.95 | x |
| 2021-12-31 | NT$2.53 | NT$22.95 | x |
| 2022-12-31 | NT$8.46 | NT$22.95 | x |
| 2023-12-31 | NT$12.93 | NT$22.95 | x |
| 2024-12-31 | NT$8.54 | NT$22.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Andros Pharmaceuticals Co.,Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38561.08%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.12x
- Recent ROE (-19.86%) is above the historical average (-28.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -39.72% | -1098.13% | 0.02x | 1.70x | NT$-44.92 Million |
| 2021 | -54.08% | -278.92% | 0.11x | 1.75x | NT$-44.00 Million |
| 2022 | -14.73% | -2403.74% | 0.01x | 1.18x | NT$-69.12 Million |
| 2023 | -14.47% | -8466.96% | 0.00x | 1.12x | NT$-115.27 Million |
| 2024 | -19.86% | -38561.08% | 0.00x | 1.12x | NT$-117.70 Million |
Industry Comparison
This section compares Andros Pharmaceuticals Co.,Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,581,964,900
- Average return on equity (ROE) among peers: 12.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Andros Pharmaceuticals Co.,Ltd (6917) | NT$357.37 Million | -39.72% | 0.11x | $6.72K |
| Synbio Tech Inc. (1295) | $758.45 Million | 17.38% | 0.83x | $20.21K |
| Apex Biotechnology Corp (1733) | $712.76 Million | 14.13% | 0.13x | $64.53 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.78 Billion | 0.44% | 0.64x | $128.24 Million |
| Panion & BF Biotech Inc (1760) | $1.35 Billion | 11.79% | 0.36x | $120.05 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.19 Billion | 20.52% | 0.94x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $2.59 Billion | 10.10% | 0.14x | $45.00 Million |
| Level Biotechnology (3118) | $549.47 Million | 11.45% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $1.48 Billion | 4.11% | 0.09x | $30.67 Million |
| Medigen Biotechnology (3176) | $2.69 Billion | -9.52% | 0.80x | $90.59 Million |
| Sagittarius Life Science (3205) | $714.71 Million | 42.07% | 0.58x | $56.62 Million |